SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-22-016242
Filing Date
2022-04-27
Accepted
2022-04-27 16:20:46
Documents
5
Period of Report
2022-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20002542x1_def14a.htm DEF 14A 1212550
2 logo_cytomx.jpg GRAPHIC 35885
3 ny20002542x1_diagram01.jpg GRAPHIC 217547
4 ny20002542x1_pc-1.jpg GRAPHIC 548369
5 ny20002542x1_pc-2.jpg GRAPHIC 544630
  Complete submission text file 0001140361-22-016242.txt   3066869
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37587 | Film No.: 22859904
SIC: 2834 Pharmaceutical Preparations